The use of radiotherapy after mastectomy: A review of the literature

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1706-1717

  Pierce, Lori J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FLUOXYMESTERONE; LEVAMISOLE; MELPHALAN; METHOTREXATE; PREDNISONE; TAMOXIFEN; TEGAFUR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; ISCHEMIC HEART DISEASE; LUNG FIBROSIS; MASTECTOMY; META ANALYSIS; PATIENT SELECTION; PERICARDITIS; PREMENOPAUSE; PRIORITY JOURNAL; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PNEUMONIA; RADIATION INJURY; SURVIVAL RATE; TIME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; PNEUMONIA; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TIME FACTORS;

EID: 15544389212     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.109     Document Type: Review

References (143)

1. Pierce LJ, Lichter AS: Defining the role of post-mastectomy radiotherapy: The new evidence. Oncology (Huntingt) 10:991-1002, 1996
2. Fowble B: Postmastectomy radiotherapy: Then and now. Oncology (Huntingt) 11:213-239, 1997
3. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997
4. Overgaard M, Jensen M-J, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 353:1641-1648, 1999
5. Ragaz J, Olivotto I, Spinelli J, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116-126, 2005
6. Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. N Engl J Med 333:1444-1455, 1995
7. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials. Lancet 355:1757-1770, 2000
8. Klefstrom P, Grohn P, Heinonen E, et al: Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 60:936-942, 1987
9. Olson JE, Neuberg D, Pandya KJ, et al: The role of radiotherapy in the management of operable locally advanced breast cancer: Results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 79:1138-1149, 1997
10. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
11. Harris J, Halpin-Murphy P, McNeese M, et al: Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44:989-990, 1999
12. Taylor M, Haffty B, Shank B, et al: Postmastectomy radiotherapy. ACR appropriateness criteria. Radiology 215:1153-1170, 2000
13. Recht A, Edge S, Solin L, et al: Postmastectomy radiotherapy guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
14. Truong P, Olivotto I, Whelan TJ, et al: Clinical Practice Guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170:1263-1273, 2004
15. Sackett D: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S-4S, 1989
16. Bedwinek J: Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 4:260-269, 1994
17. Morrison J, Kelly K, Howell A, et al: West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr:85-88, 1992
18. Zambetti M, Valagussa P, Bonadonna G: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Ann Oncol 7:481-485, 1996
19. Goldhirsch A, Castiglione M, Gelber R, et al: A single perioperative adjuvant chemotherapy course for node-negative breast cancer: Five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr:89-96, 1992
20. Mansour E, Eudey L, Tormey D, et al: Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr:97-104, 1992
21. Fisher B, Dignam J, Eleftherios P, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from national surgical adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14:1982-1992, 1996
22. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
23. Fisher B, Fisher E: Redmond C and participating NSABP Investigators: Ten-year results from the national surgical adjuvant breast and bowel project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-941, 1986
24. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 332:901-906, 1995
25. Rubens RD, Knight RK, Fentiman IS, et al: Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet 1:839-843, 1983
26. Richards MA, O'Reilly SM, Howell A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol 8:2032-2039, 1990
27. Morrison J, Howell A, Kelly K, et al: West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: Results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. Br J Cancer 60:911-918, 1989
28. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International (Ludwig) Breast Cancer Study Group Trials I-IV: 5 years follow-up. Ann Oncol 5:717-724, 1994
29. Crivellari D, Price K, Gelber R, et al: Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group trial IV. J Clin Oncol 21:4517-4523, 2003
30. Taylor S, Knuiman W, Sleeper L, et al: Six-year results of the Eastern Cooperative Oncology Group Trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 7:879-889, 1989
31. Ingle J, Everson L, Wieand S, et al: Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 6:1388-1396, 1988
32. Wood W, Budman D, Korzun A, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
33. Fisher B, Anderson S, Wickerham D, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National and Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
34. Hoeller U, Heide J, Kroeger N, et al: Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer. Int J Radiat Oncol Biol Phys 53:1234-1239, 2002
35. Marks L, Halperin E, Prosnitz L, et al: Postmastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with > 10 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 23:1021-1026, 1992
36. Buchholz T, Tucker S, Moore R, et al: Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys 46:337-343, 2000
37. Sartor C, Peterson B, Woolf S, et al: Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 23:30-40, 2005
38. Bellon J, Harris J: Chemotherapy and radiation therapy for breast cancer: What is the optimal sequence? J Clin Oncol 23:5-7, 2005
39. Citron M, Berry D, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
40. Pierce L, Lichter A: Postmastectomy radiotherapy: More than locoregional control. J Clin Oncol 12:444-446, 1994
41. Stjernsward J: Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 2:1285-1286, 1974
42. Cuzick J, Stewart H, Peto R, et al: Overview of randomized trials of post-operative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 71:15-25, 1987
43. Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
44. Van de Steene J, Soete G, Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link. Radiother Oncol 55:263-272, 2000
45. Whelan TJ, Julian J, Wright J, et al: Does loco-regional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18:1220-1229, 2000
46. LeLorier J, Gregoire G, Benhaddad A, et al: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337:536-542, 1997
47. Martinez A, Ahmann D, O'Fallow J, et al: An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer. Int J Radiat Oncol Biol Phys 10:106, 1984 (suppl 2)
48. Griem KL, Henderson IC, Gelman R, et al: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 5:1546-1555, 1987
49. McArdle CS, Crawford D, Dykes EH, et al: Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 73:264-266, 1986
50. Muss HB, Cooper MR, Brockschmidt JK, et al: A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Eleven year follow-up of a Piedmont Oncology Association Trial. Breast Cancer Res Treat 19:77-84, 1991
51. Velez-Garcia E, Carpenter J, Jr., Moore M, et al: Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A South-Eastern Cancer Study Group (SEG) Trial. Eur J Cancer 28:1833-1837, 1992
52. Buzdar A, Hortobagyi G, Kau S, et al: Breast cancer adjuvant therapy at the M.D. Anderson Cancer Center-Results of four prospective studies, in Salmon SE (ed): Adjuvant Therapy of Cancer VII. Philadelphia, PA, J.B. Lippincott, pp 220-231, 1993
53. Tennvall-Nittby L, Tengrup I, Landberg T: The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial. Acta Oncol 32:641-646, 1993
54. Blomqvist C, Tiusanen K, Elomaa I, et al: The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. Br J Cancer 66:1171-1176, 1992
55. Katz A, Strom EA, Buchholz TA, et al: Loco-regional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 18:2817-2827, 2000
56. Recht A, Gray R, Davidson NE, et al: Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17:1689-1700, 1999
57. Taghian A, Jeong J, Anderson S, et al: Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: Results from five National Surgical Adjuvant Breast and Bowel Project randomized trials. J Clin Oncol 22:4247-4254, 2004
58. Mauriac L, Luprosi E, Cutuli B, et al: Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001). Br J Cancer 89:S-17-S31, 2003 (suppl 1)
59. Bartelink H: Post-mastectomy radiotherapy: Recommended standards. Ann Oncol 11:7-11, 2000 (suppl 3)
60. rd Edition. Philadelphia, PA, W.B. Saunders, 1986
61. Overgaard M: Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol 9:292-299, 1999
62. Benson EA, Thorogood J: The effect of surgical technique on local recurrence rates following mastectomy. Eur J Surg Oncol 12:267-271, 1986
63. Delouche G, Bachelot F, Premont M, et al: Conservation treatment of early breast cancer: Long term results and complications. Int J Radiat Oncol Biol Phys 13:29-34, 1987
64. Iyer R, Hanlon A, Fowble B, et al: Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys 47:1177-1183, 2000
65. Ragaz J, Jackson S, Le N, et al: Survival gains of locoregional radiation (RT) in breast cancer with 1-3 positive axillary nodes (N1-3): Locoregional recurrences (LocRecs) are NOT a useful guide to predict the benefit of the RT-An update from the British Columbia (BC) randomized trial. Proc Am Soc Clin Oncol 19:82a, 2000 (abstr 312)
66. Wallgren A, Bonetti M, Gelber RD, et al: Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21:1205-1213, 2003
67. Helinto M, Blomqvist C, Heikkila P, et al: Post-mastectomy radiotherapy in pT3NOMO breast cancer: Is it needed? Radiother Oncol 52:213-217, 1999
68. Beenken SW, Urist MM, Zhang Y, et al: Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 237, 732-738, 2003
69. Mignano JE, Gage I, Piantadosi S, et al: Local recurrence after mastectomy in patients with T3NO breast carcinoma treated without postoperative irradiation. Breast Cancer Res Treat 41:255, 1996 (abstr 230)
70. Donegan W, Stine S, Samter T: Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 72:778-782, 1993
71. Hetelekidis S, Schnitt S, Silver B, et al: The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys 46:31-34, 2000
72. Mignano J, Zahurak M, Chakravarthy A, et al: Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer 86:1258-1262, 1999
73. Leonard C, Corkill M, Tompkin J, et al: Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer: Implications for radiation therapy. J Clin Oncol 13:47-53, 1995
74. Pierce L, Oberman H, Strawderman M, et al: Microscopic extracapsular extension in the axilla: Is this an indication for axillary radiotherapy? Int J Radiat Oncol Biol Phys 33:253-259, 1995
75. Gruber G, Berclaz G, Altermatt H-J, et al: Can the addition of regional radiotherapy counter-balance important risk factors in breast cancer patients with extracapsular invasion of axillary lymph node metastases? Strahlenther Onkol 179:661-666, 2003
76. Ragaz J, Jackson E, Le N, et al: Postmastectomy radiation (RT) outcome in node (N) positive breast cancer patients among N 1-3 versus N4+ subset: Impact of extracapsular spread (ES). Update of the British Columbia randomized trial. Proc Am Soc Clin Oncol 18:73a, 1999 (abstr 274)
77. Kuske RR, Sanchez M, Farr GH, et al: Extracapsular axillary nodal extension (ECE) in breast cancer: Patterns of recurrence, arm edema, and survival after mastectomy with and without irradiation. Int J Radiat Oncol Biol Phys 45:157, 1999
78. Ilknur G, Hilmi A, Tulay C, et al: The importance of extracapsular extension of axillary lymph node metastases in breast cancer. Tumori 90:107-111, 2004
79. Ahlborn TN, Gump FE, Bodian C, et al: Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy. Surg Gynecol Obstet 166:523-526, 1988
80. Mentzer SJ, Osteen RT, Wilson RE: Local recurrence and the deep resection margin in carcinoma of the breast. Surg Gynecol Obstet 163:513-517, 1986
81. Katz A, Strom EA, Buchholz TA, et al: Locoregional recurrence patterns after mastectomy and doxorubicin based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 18:2817-2827, 2000
82. Freedman GM, Fowble BL, Hanlon AL, et al: A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J. Radiat Oncol Biol Phys 41:599-605, 1998
83. Truong PT, Olivotto IA, Speers CH, et al: A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J. Radiat Oncol Biol Phys 58:797-804, 2004
84. Pisansky TM, Ingle JN, Schaid DJ, et al: Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer 72:1247-1260, 1993
85. O'Rourke S, Galea MH, Morgan D, et al: Local recurrence after simple mastectomy. Br J Surg 81:386-389, 1994
86. Stal O, Sullivan S, Wingren S, et al: c-erB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
87. Zellars RC, Clark GM, Allred DC, et al: Prognostic value of p53 for local failure in mastectomy treated breast cancer patients. Proc Am Soc Clin Oncol 17:104a, 1998 (abstr 401)
88. Silvestrini R, Veneroni S, Benini E, et al: Expression of p53, glutathione s-transferase-π, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639-645, 1997
89. Lampe B, Hantschmann P, Dimpfl Th: Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer. Arch Gynecol Obstet 261:139-146, 1998
90. Ewers SB, Attewell R, Baldetorp B, et al: Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer. Acta Oncol 31:733-740, 1992
91. Strom EA, McNeese MD: Postmastectomy irradiation rationale for treatment field selection. Semin Radiat Oncol 9:247-253, 1999
92. Halverson KJ, Perez CA, Kuske RR, et al: Isolated local-regional recurrence of breast cancer following mastectomy: Radiotherapeutic management. Int J Radiat Oncol Biol Phys 19:851-858, 1990
93. Schwaibold R, Fowble BL, Solin LJ, et al: The results of radiation therapy for isolated local regional recurrences after mastectomy. Int J Radiat Oncol Biol Phys 21:299-310, 1991
94. Dahl-Iverson E: Rechereches sur les metastases microscopiques des cancers du sein dans les ganglions lymphatiques parasternaux et susclaviculaires. Mem Acad Clin 78:651-663, 1952
95. Nguyen-Tan PF, Vincent L, Methot F, et al: The incidence of supraclavicular failure in patients with T1-2 breast cancer and four or more positive nodes treated by conservative surgery and tangential breast irradiation without regional nodal irradiation. Int J Radiat Oncol Biol Phys 42:249, 1998 (suppl 1)
96. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
97. Larson D, Weinstein M, Goldberg I, et al: Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 12:1575-1582, 1986
98. Kissin MW, Querci della Rovere G, Easton D, et al: Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73:580-584, 1986
99. Handley RS: Carcinoma of the breast. Ann R Coll Surg Engl 57:59-66, 1975
100. Noguchi M, Ohta N, Thomas M, et al: Risk of internal mammary lymph node metastases and its prognostic value in breast cancer patients. J Surg Oncol 52:26-30, 1993
101. Obedian E, Lafty B: No benefit to intentionally targeting the internal mammary lymph nodes in conservatively managed breast cancer patients. Int J Radiat Oncol Biol Phys 42:246, 1998 (suppl 1)
102. Veronesi U, Marubini E, Mariani L, et al: The dissection of internal mammary nodes does not improve the survival of breast cancer patients: 30-year results of a randomized trial. Eur J Cancer 35:1320-1325, 1999
103. Arriagada R, Le MG, Mouriesse H, et al: Long-term effect of internal mammary chain treatment: Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother Oncol 11:213-222, 1988
104. Romestaing P, Ecochard R, Hennequin C, et al: Role of irradiation of internal mammary chain after mastectomy: A French S.F.R.O. phase III randomized trial. Radiother Oncol 48:5119, 1998 (suppl 1)
105. Metz JM, Schultz DJ, Fox K, et al: Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence. Cancer J Sci Am 5:77-83, 1999
106. Madu C, Quint D, Normolle D, et al: Definition of the supraclavicular and infraclavicular nodes: Implications for three-dimensional CT-based conformal radiation therapy. Radiology 221:333-339, 2001
107. Lingos TI, Recht A, Vicini F, et al: Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21:355-360, 1991
108. Taghian AG, Assaad SI, Niemierko A, et al: Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93:1806-1811, 2001
109. Hanna YM, Baglan KL, Stromberg JS, et al: Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 8:149-153, 2002
110. Pierce LJ, Butler JB, Martel MK, et al: Postmastectomy radiotherapy of the chest wall: Dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys 52:1220-1230, 2002
111. Hojris I, Andersen J, Overgaard M, et al: Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 39:355-372, 2000
112. Corn BW, Trock BJ, Goodman RL: Irradiation-related ischemic heart disease. J Clin Oncol 8:741-750, 1990
113. Shapiro CL, Hardenbergh PH, Gelman R, et al: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493-3501, 1998
114. Gyenes G, Rutqvist LE, Liedberg A, et al: T. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol 48:185-190, 1998
115. Rutqvist LE, Lax I, Fornander T, et al: Cardiovascular mortality in a randomized trial of adjuvant radiation versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22:887-896, 1992
116. Paszat LF, Mackillop WJ, Groome PA, et al: Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology and End Results cancer registries. J Clin Oncol 16:2625-2631, 1998
117. Rutqvist LE, Liedberg A, Hammar N, et al: Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 40:359-363, 1998
118. Nixon AJ, Manola J, Gelman R, et al: No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 16:1374-1379, 1998
119. Gustavsson A, Bendahl P-O, Cwikiel M, et al: No serious late cardiac effects after adjuvant radiotherapy following mastectomy in premenopausal women with early breast cancer, Int J Radiat Oncol Biol Phys 43:745-754, 1999
120. Hojris I, Overgaard M, Christensen JJ, et al: Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Lancet 354:1425-1430, 1999
121. Krueger EA, Fraass BA, McShan DL, et al: Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 56:1023-1037, 2003
122. Bellon JR, Come SE, Gelman RS, et al: Sequencing of chemotherapy and radiation therapy for patients with early stage breast cancer: Updated results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 51:2, 2001 (suppl 1)
123. Rouesse J, Cvitkovic F, DeLalande B, et al: Concomitant or sequential chemo-radiotherapy (CRT) in operable breast cancer. Final results of a French multicentric phase III study. Breast Cancer Res Treat 76:S160, 2002
124. Galais G, Serin D, Foourquet A, et al. Randomized study comparing adjuvant radiotherapy (RT) with concomitant chemotherapy (CT) versus sequential treatment after conservative surgery for patients with stages I and II breast carcinoma. Int J Radiat Oncol Biol Phys 54:57-58, 2002 (suppl 2; abstr)
125. Raynaud-Bougnoux A, Mercier P, Descamps P, et al: Postoperative radiotherapy and concomitant adjuvant chemotherapy for breast carcinoma. Eur J Cancer 31A:S16-S17, 1995 (suppl 5; abstr)
126. Formenti SC, Symmans WF, Volm M, et al: Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 2:34-42, 1999 (suppl 1)
127. Markiewicz DA, Schultz DJ, Haas JA, et al: The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy, Int J Radiat Oncol Biol Phys 35:661-668, 1996
128. Dubey A, Recht A, Come SE, et al: Concurrent CMF and radiation therapy for early stage breast cancer: Results of a pilot study. Int J Radiat Oncol Biol Phys 45:877-884, 1999
129. th EORTC Breast Cancer Working Conference, Leuven, Belgium, A293, 1991 (abstr)
130. Pierce L, Hutchins L, Green S, et al: Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early stage breast cancer. J Clin Oncol 23:24-29, 2005
131. Harris E, Christensen V, Hwang W-T, et al: Impact of concurrent versus sequential tamoxifen and radiation therapy in early stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23:11-16, 2005
132. Ahn P, Vu T, Lannin D, et al: Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23:17-23, 2005
133. Whelan T, Levine M: Radiation therapy and tamoxifen: Concurrent or sequential? That is the question. J Clin Oncol 23:1-4, 2005
134. Garg A, Strom E, McNeese M, et al: T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59:138-145, 2004
135. Buchholz TA, Tucker SL, Masullo L, et al: Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20:17-23, 2001
136. Mamounas EP, Wang J, Bryant J, et al: Patterns of loco-regional failure (LRF) in patients receiving neoadjuvant chemotherapy (NC): Results from NSABP B-18. Breast Cancer Res Treat 82:317, 2003 (abstr 35; suppl 1)
137. Krueger EA, Wilkins EG, Strawderman M, et al: Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J. Radiat Oncol Biol Phys 49:713-721, 2001
138. Chawla A, Kachnic L, Taghian A, et al: Radiotherapy and breast reconstruction: Complications and cosmesis with TRAM versus tissue expander/implant. Int J Radiat Oncol Biol Phys 54:520-526, 2002
139. Alderman A, Wilkins E, Kim H, et al: Complications in postmastectomy breast reconstruction: Two-year results of the Michigan Breast Reconstruction Outcome study. Plast Reconstr Surg 109:2265-2274, 2002
140. Soong IS, Yau TK, Ho CM, et al: Post-mastectomy radiotherapy after immediate autologous breast reconstruction in primary treatment of breast cancers. Clin Oncol (R Coll Radiol) 16:283-289, 2004
141. Mehta V, Goffinet D: Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J 10:118-122, 2004
142. Pierce L, Moughan J, White J, et al: 1998-1999 patterns of care survey (PCS) update of national practice patterns using breast-conserving surgery (BCS) and radiotherapy (RT) in the management of stage I/II breast cancer. Int J Radiat Oncol Biol Phys 54:59, 2002 (abstr 97; suppl 2)
143. Sixel K, Aznar M, Ung Y: Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol Phys 49:199-204, 2001